Biotech Stocks Soar in After-Hours Trading: PCSA, PALI, and QTTB Top the Charts in Volume and Speculation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 08 2025
0mins
Should l Buy PALI?
Source: NASDAQ.COM
Processa Pharmaceuticals Surge: Processa Pharmaceuticals Inc. (PCSA) saw a significant after-hours gain of 40.3%, closing at $0.51, driven by speculative momentum and unusually high trading volume of over 200 million shares.
Palisade Bio's Volatility: Palisade Bio Inc. (PALI) experienced an 11.9% rise in after-hours trading to $1.88, following a recent $138 million public offering and positive clinical trial results for its ulcerative colitis treatment.
Q32 Bio's Speculative Rise: Q32 Bio Inc. (QTTB) rose 26.6% in after-hours trading to $3.19, with the increase attributed to speculative trading ahead of its upcoming earnings report, despite no new company announcements.
Market Activity Overview: The sharp gains in these small-cap biotech stocks reflect a mix of speculative trading, clinical updates, and capital market activities, highlighting the volatility in the biotech sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PALI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PALI
Wall Street analysts forecast PALI stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.740
Low
7.00
Averages
13.00
High
25.00
Current: 1.740
Low
7.00
Averages
13.00
High
25.00
About PALI
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Palisade Bio to Participate in Immunology Symposium
- Virtual Fireside Chat: Palisade Bio will participate in the Piper Sandler Virtual Immunology Symposium on February 12, 2026, from 1:30 PM to 1:55 PM ET, featuring CEO JD Finley and CMO Dr. Mitchell Jones discussing the company's innovations in immunology.
- PALI-2108 Drug Development: PALI-2108 is a once-daily oral PDE4 inhibitor prodrug designed for targeted activation in the terminal ileum and colon, aimed at improving pharmacology and tolerability for patients with inflammatory and fibrotic diseases.
- Clinical Trial Results: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in ulcerative colitis patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics consistent with localized activation.
- Future Research Plans: The company is advancing towards a Phase 2 clinical study for PALI-2108, designed to evaluate clinical remission, response, and pharmacodynamic biomarkers over 12 weeks, with an extension phase to assess maintenance of remission.
See More
Palisade Bio's PALI-2108 Clinical Data Selected for Two International IBD Meetings
- Clinical Data Presentation: Palisade Bio's PALI-2108 has been selected for poster presentations at two international inflammatory bowel disease meetings in January and February 2026, showcasing the drug's potential in ulcerative colitis treatment and enhancing the company's reputation in the biopharmaceutical sector.
- Immune Balance Restoration: PALI-2108 rapidly restores immune-epithelial balance in ulcerative colitis patients through gut-targeted PDE4B inhibition, indicating its clinical efficacy and potentially providing new treatment options for patients.
- Successful Clinical Trials: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in ulcerative colitis patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics, which strengthens its market competitiveness.
- Future Research Plans: Palisade Bio plans to initiate a Phase 2 clinical study for PALI-2108 in 2026 to evaluate clinical remission and pharmacodynamic biomarkers in ulcerative colitis, further validating its therapeutic effects and expanding its indications.
See More
Palisade Bio Secures $500K Investment to Advance PALI-2108
- Strategic Investment: The Crohn’s & Colitis Foundation has approved a strategic equity investment of up to $500,000 in Palisade Bio through its IBD Ventures program, aimed at supporting the clinical and mechanistic development of PALI-2108, reflecting strong endorsement of the drug's potential.
- Clinical Progress: PALI-2108 achieved a 100% clinical response in the UC cohort with no serious adverse events, indicating favorable tolerability and pharmacokinetics in treating moderate to severe ulcerative colitis and fibrostenotic Crohn’s disease.
- R&D Plans: Palisade Bio is preparing to submit a Phase 2 Investigational New Drug application to the FDA in 2026 for PALI-2108, further advancing its clinical development to meet the urgent need for non-immunosuppressive therapies for patients.
- Market Potential: The targeted delivery design of PALI-2108 aims to minimize systemic side effects while maximizing anti-inflammatory and anti-fibrotic effects, which is expected to significantly enhance treatment options for IBD patients and strengthen the company's competitive position in the biopharmaceutical sector.
See More
Momentus Inc. Shares Surge 57% Following Fuel Tank Development Announcement
- Stock Surge: Momentus Inc. shares soared 57% to $8.98 following the announcement of an additive-manufactured fuel tank, indicating strong market confidence in its aerospace service potential.
- Flight Testing Plans: The fuel tank is scheduled for flight testing aboard the Vigoride-7 orbital service vehicle, which not only enhances the company's technological capabilities but also opens new revenue streams for future commercial launches.
- FDA Clearance: GH Research PLC shares rose 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application, marking a significant breakthrough in the company's development process that could accelerate product commercialization.
- Market Volatility: Despite a generally positive market, Zenas Biopharma Inc. shares plummeted 57% due to results from the INDIGO trial, reflecting the high-risk nature of the biopharmaceutical sector, necessitating cautious investment evaluations.
See More
Palisade Bio Secures Japanese Patent for PALI-2108, Phase 2 Trials Planned for 2026
- Patent Protection: Palisade Bio has secured a Japanese patent for PALI-2108, which extends until 2041, ensuring a unique competitive advantage in the Japanese market to meet the urgent needs of ulcerative colitis and Crohn's disease patients.
- Clinical Progress: PALI-2108 demonstrated a 100% clinical response rate in Phase 1 trials with no serious adverse events, laying a solid foundation for the upcoming Phase 2 IND submission planned for the first half of 2026.
- Market Potential: Japan represents one of the largest markets for inflammatory bowel disease globally, and the patent acquisition will enhance Palisade Bio's strategic position in this market, expected to significantly boost product acceptance and sales potential.
- Innovative Drug Development: PALI-2108 is designed for local delivery to minimize systemic side effects, which is anticipated to provide safer treatment options for patients, thereby driving the company's long-term growth in chronic inflammatory and fibrotic diseases.
See More
Palisade Bio Secures Japanese Patent for PALI-2108, IND Submission Planned for 2026
- Strengthened Patent Protection: Palisade Bio has secured a Japanese patent for PALI-2108, effective until 2041, which enhances the company's intellectual property foundation in the inflammatory bowel disease (IBD) sector, potentially boosting market competitiveness.
- Accelerated Clinical Progress: The ongoing development of PALI-2108 for UC and FSCD is on track, with an IND submission to the FDA planned for the first half of 2026, which, if successful, will provide more effective treatment options for patients and meet market demand.
- Significant Clinical Trial Results: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in UC patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics, which may enhance market acceptance.
- Substantial Market Potential: Japan represents one of the largest markets for IBD globally, and the patent protection along with clinical advancements for PALI-2108 will help the company capture long-term growth opportunities in the region while improving patient outcomes.
See More
Palisade Bio to Participate in Immunology Symposium
- Virtual Fireside Chat: Palisade Bio will participate in the Piper Sandler Virtual Immunology Symposium on February 12, 2026, from 1:30 PM to 1:55 PM ET, featuring CEO JD Finley and CMO Dr. Mitchell Jones discussing the company's innovations in immunology.
- PALI-2108 Drug Development: PALI-2108 is a once-daily oral PDE4 inhibitor prodrug designed for targeted activation in the terminal ileum and colon, aimed at improving pharmacology and tolerability for patients with inflammatory and fibrotic diseases.
- Clinical Trial Results: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in ulcerative colitis patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics consistent with localized activation.
- Future Research Plans: The company is advancing towards a Phase 2 clinical study for PALI-2108, designed to evaluate clinical remission, response, and pharmacodynamic biomarkers over 12 weeks, with an extension phase to assess maintenance of remission.
See More
Palisade Bio's PALI-2108 Clinical Data Selected for Two International IBD Meetings
- Clinical Data Presentation: Palisade Bio's PALI-2108 has been selected for poster presentations at two international inflammatory bowel disease meetings in January and February 2026, showcasing the drug's potential in ulcerative colitis treatment and enhancing the company's reputation in the biopharmaceutical sector.
- Immune Balance Restoration: PALI-2108 rapidly restores immune-epithelial balance in ulcerative colitis patients through gut-targeted PDE4B inhibition, indicating its clinical efficacy and potentially providing new treatment options for patients.
- Successful Clinical Trials: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in ulcerative colitis patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics, which strengthens its market competitiveness.
- Future Research Plans: Palisade Bio plans to initiate a Phase 2 clinical study for PALI-2108 in 2026 to evaluate clinical remission and pharmacodynamic biomarkers in ulcerative colitis, further validating its therapeutic effects and expanding its indications.
See More
Palisade Bio Secures $500K Investment to Advance PALI-2108
- Strategic Investment: The Crohn’s & Colitis Foundation has approved a strategic equity investment of up to $500,000 in Palisade Bio through its IBD Ventures program, aimed at supporting the clinical and mechanistic development of PALI-2108, reflecting strong endorsement of the drug's potential.
- Clinical Progress: PALI-2108 achieved a 100% clinical response in the UC cohort with no serious adverse events, indicating favorable tolerability and pharmacokinetics in treating moderate to severe ulcerative colitis and fibrostenotic Crohn’s disease.
- R&D Plans: Palisade Bio is preparing to submit a Phase 2 Investigational New Drug application to the FDA in 2026 for PALI-2108, further advancing its clinical development to meet the urgent need for non-immunosuppressive therapies for patients.
- Market Potential: The targeted delivery design of PALI-2108 aims to minimize systemic side effects while maximizing anti-inflammatory and anti-fibrotic effects, which is expected to significantly enhance treatment options for IBD patients and strengthen the company's competitive position in the biopharmaceutical sector.
See More
Momentus Inc. Shares Surge 57% Following Fuel Tank Development Announcement
- Stock Surge: Momentus Inc. shares soared 57% to $8.98 following the announcement of an additive-manufactured fuel tank, indicating strong market confidence in its aerospace service potential.
- Flight Testing Plans: The fuel tank is scheduled for flight testing aboard the Vigoride-7 orbital service vehicle, which not only enhances the company's technological capabilities but also opens new revenue streams for future commercial launches.
- FDA Clearance: GH Research PLC shares rose 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application, marking a significant breakthrough in the company's development process that could accelerate product commercialization.
- Market Volatility: Despite a generally positive market, Zenas Biopharma Inc. shares plummeted 57% due to results from the INDIGO trial, reflecting the high-risk nature of the biopharmaceutical sector, necessitating cautious investment evaluations.
See More
Palisade Bio Secures Japanese Patent for PALI-2108, Phase 2 Trials Planned for 2026
- Patent Protection: Palisade Bio has secured a Japanese patent for PALI-2108, which extends until 2041, ensuring a unique competitive advantage in the Japanese market to meet the urgent needs of ulcerative colitis and Crohn's disease patients.
- Clinical Progress: PALI-2108 demonstrated a 100% clinical response rate in Phase 1 trials with no serious adverse events, laying a solid foundation for the upcoming Phase 2 IND submission planned for the first half of 2026.
- Market Potential: Japan represents one of the largest markets for inflammatory bowel disease globally, and the patent acquisition will enhance Palisade Bio's strategic position in this market, expected to significantly boost product acceptance and sales potential.
- Innovative Drug Development: PALI-2108 is designed for local delivery to minimize systemic side effects, which is anticipated to provide safer treatment options for patients, thereby driving the company's long-term growth in chronic inflammatory and fibrotic diseases.
See More
Palisade Bio Secures Japanese Patent for PALI-2108, IND Submission Planned for 2026
- Strengthened Patent Protection: Palisade Bio has secured a Japanese patent for PALI-2108, effective until 2041, which enhances the company's intellectual property foundation in the inflammatory bowel disease (IBD) sector, potentially boosting market competitiveness.
- Accelerated Clinical Progress: The ongoing development of PALI-2108 for UC and FSCD is on track, with an IND submission to the FDA planned for the first half of 2026, which, if successful, will provide more effective treatment options for patients and meet market demand.
- Significant Clinical Trial Results: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in UC patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics, which may enhance market acceptance.
- Substantial Market Potential: Japan represents one of the largest markets for IBD globally, and the patent protection along with clinical advancements for PALI-2108 will help the company capture long-term growth opportunities in the region while improving patient outcomes.
See More
